(GMAB) Genmab - Performance -24.6% in 12m
GMAB performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-62.41%
#88 in Peer-Group
Rel. Strength
19.21%
#6229 in Stock-Universe
Total Return 12m
-24.63%
#91 in Peer-Group
Total Return 5y
-42.73%
#57 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | 12.7 |
| P/E Forward | 12.1 |
| High / Low | DKK |
|---|---|
| 52 Week High | 1967.00 DKK |
| 52 Week Low | 1168.50 DKK |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 22.31 |
| Buy/Sell Signal +-5 | -1.32 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: GMAB (-24.6%) vs XBI (-7.2%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.11% | 68.3% | 77.5% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.3% | -6.89% | 148% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.9% | -1.4% | 35.4% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
0.57% | 33% | -5.3% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.89% | -5.88% | 1.36% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.2% | 59.2% | -5.89% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
0.66% | 61.7% | -9.1% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
3.23% | 38.8% | 14.5% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: GMAB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for GMAB
| Total Return (including Dividends) | GMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -8.96% | 4.38% | 4.99% |
| 3 Months | 1.61% | 5.22% | 10.23% |
| 12 Months | -24.63% | -7.16% | 14.42% |
| 5 Years | -42.73% | -24.61% | 110.17% |
| Trend Score (consistency of price movement) | GMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -82.3% | 4.4% | 81% |
| 3 Months | 43.9% | 78.8% | 96.9% |
| 12 Months | -85.9% | -85.8% | 44.9% |
| 5 Years | -56.4% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th23.50 | -12.78% | -13.29% |
| 3 Month | %th46.50 | -3.43% | -7.83% |
| 12 Month | %th55.50 | -18.82% | -34.13% |
| 5 Years | %th73.00 | -24.04% | -72.75% |
FAQs
Does Genmab (GMAB) outperform the market?
No,
over the last 12 months GMAB made -24.63%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.16%.
Over the last 3 months GMAB made 1.61%, while XBI made 5.22%.
Performance Comparison GMAB vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
GMAB vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.7% | -14% | -22.1% | -39% |
| US NASDAQ 100 | QQQ | -3.3% | -14.4% | -23.6% | -38% |
| German DAX 40 | DAX | -2.7% | -8.4% | -33.7% | -55% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -0.9% | -13.1% | -22.6% | -42% |
| Hongkong Hang Seng | HSI | -1.7% | -16.1% | -40.6% | -61% |
| India NIFTY 50 | INDA | -2.6% | -10.9% | -19.5% | -24% |
| Brasil Bovespa | EWZ | -6.3% | -17% | -45% | -38% |
GMAB vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -3.6% | -14.7% | -26.4% | -51% |
| Consumer Discretionary | XLY | -4.8% | -11.8% | -15.2% | -44% |
| Consumer Staples | XLP | -4% | -8.8% | -21.5% | -35% |
| Energy | XLE | -4.3% | -15.1% | -17.3% | -23% |
| Financial | XLF | -3.8% | -12.5% | -25.3% | -53% |
| Health Care | XLV | -2.6% | -11.4% | -14.6% | -20% |
| Industrial | XLI | -4.5% | -13.2% | -28.9% | -49% |
| Materials | XLB | -6.8% | -14.8% | -26.3% | -32% |
| Real Estate | XLRE | -2.8% | -9.8% | -20.7% | -38% |
| Technology | XLK | -3.2% | -18% | -25.1% | -36% |
| Utilities | XLU | -2.4% | -8.5% | -23.4% | -48% |
| Aerospace & Defense | XAR | -3.9% | -16.5% | -40.4% | -73% |
| Biotech | XBI | -3.3% | -13.3% | -8% | -17% |
| Homebuilder | XHB | -8.6% | -20.6% | -16.1% | -31% |
| Retail | XRT | -6.3% | -14.5% | -16.9% | -35% |
GMAB vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -4.6% | -17.6% | -13.6% | -18% |
| Natural Gas | UNG | 1.2% | -0.4% | -6% | -19% |
| Gold | GLD | -2.2% | -8.2% | -41.4% | -68% |
| Silver | SLV | -2.2% | -14.2% | -38.8% | -48% |
| Copper | CPER | -6% | -15.1% | -42.7% | -42% |
GMAB vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -1.9% | -12.2% | -17.5% | -25% |
| iShares High Yield Corp. Bond | HYG | -2.2% | -10.9% | -20.2% | -35% |